Changchun High-Tech's Jinsai Pharma Wins NMPA Approval for GenSci148 Injection Trials in nAMD, DME and RVO
Changchun High-Tech announced on August 10 that its subsidiary Changchun Jinsai Pharmaceutical Co. , Ltd. has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration, approving the company's domestic drug registration clinical trial application for GenSci148 Injection.
GenSci148 Injection is a multi-target VEGF blocker independently developed by Jinsai Pharmaceutical. Classified as a Class 1 therapeutic biological product, it is intended for the treatment of neovascular age-related macular degeneration, diabetic macular edema and retinal vein occlusion.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Biotechnology, with intensity 40/100 and 60% confidence over a medium term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.